For decades, clinical trials have struggled to reconcile that patients most affected by disease are often the least represented in research. Underdiagnosed populations, misdiagnosed patients, and individuals outside traditional healthcare pathways remain largely absent from clinical trials, which limits both scientific insight and equitable access to innovation.
This challenge matters more now than ever. Trials are larger and more complex, regulators are increasing expectations around diversity and real-world relevance, and patients themselves are demanding greater transparency and access. Yet many recruitment strategies still rely heavily on site-based models, addressing patients covered by the sites’ patient networks. As a result, many patients remain unreached, even those most affected by the disease under study. Digital patient recruitment is proving to be not just an alternative, but an even more effective approach.
The limits of site-based recruitment
Site-based recruitment starts with patients already inside the healthcare system: those seeing specialists, visiting academic centers, or captured in site databases. This inherently excludes patients who are undiagnosed, misdiagnosed, geographically distant, or disengaged from formal care. This results in a narrow and repetitive recruitment pool.
Evidence shows how significant this gap truly is. A 2025 study published by Roos et al. in the Journal of Medical Internet Research used digital outreach to engage women experiencing menstrual pain and found that over 95% of participants reporting symptoms consistent with dysmenorrhea had never received a formal diagnosis. More than 90% had either not sought medical care, were uncertain about their diagnosis, or had symptoms dismissed or unrecognized by providers.
These patients would never appear in site databases, yet they represent a substantial, clinically relevant population.
Why digital recruitment reaches patients sites cannot
Digital recruitment flips the model. Instead of starting at the site, it starts where patients already search for answers.
Under- and misdiagnosed patients often turn to the internet long before they enter specialty care. They search for symptoms, explore patient forums, and seek validation for experiences that may have gone unrecognized for years. Digital recruitment intercepts those moments with education-first messaging and clear pathways to research participation.
Roos et al. demonstrate this clearly: online campaigns successfully identified large numbers of symptomatic individuals who were entirely outside traditional medical pathways, underscoring digital outreach’s ability to surface patients invisible to site-based recruitment.
Digital recruitment is also more scalable and efficient. A 2025 study by Haas et al. in JMIR Mental Health that compares social media–based recruitment with offline methods found that online recruitment reached eligible participants faster while maintaining comparable clinical validity. Importantly, optimized digital campaigns that used tools like video ads and pixel tracking reduced the cost per eligible participant by over 80%, making recruitment up to six times more cost-efficient than less targeted approaches. These efficiencies matter most in large Phase III trials, where speed, cost control, and global reach are critical.
Why this matters now
The gap between trial populations and real-world patients is widening. Complex protocols, global enrollment requirements, and increasing expectations around inclusivity demand recruitment strategies that extend beyond the walls of research sites.
Digital recruitment is no longer experimental. It is one of the few scalable ways to reach patients who are early in their diagnostic journeys, navigating fragmented care, or excluded by geography, language, or access barriers.
Crucially, digital recruitment does not replace sites — it strengthens them. By delivering informed, pre-qualified patients to sites, it reduces site burden while expanding reach and diversity.
Let’s rethink the starting point
The future of patient recruitment is not a choice between digital and site-based methods, but a decision about where we begin.
If we continue to start at the site, we will continue to find the same patients. If we start with where patients search, question, and seek understanding, we can finally reach the populations that clinical research has long missed.The data is clear. Digital patient recruitment challenges us to rethink access, representation, and responsibility in clinical research. The question now is whether we are willing to design trials around real patient journeys or continue to accept the limits of the systems we’ve always used.
Photo by Getty Images
Suzanne Harris is a patient advocate and Senior Vice President of Marketing & Communications at SubjectWell. SubjectWell challenges sponsors, CROs and sites to rethink patient recruitment by providing the most patient-centric solutions that address the greatest challenges in clinical development.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
